Viral Therapy in Treating Patients With Metastatic Melanoma

NCT ID: NCT00651157

Last Updated: 2014-04-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-30
• Study Completion Date: 2012-10-31

Brief Summary

This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.

Detailed Description

PRIMARY OBJECTIVES:

I. Assess the antitumor effect of wild-type reovirus (Reolysin®), in terms of tumor response rate and clinical benefit rate (i.e., partial response and complete response), in patients with metastatic melanoma.

II. Assess the toxicity profile of Reolysin® in these patients.

SECONDARY OBJECTIVES:

I. Assess the progression-free survival and overall survival of these patients. II. Assess viral replication in metastatic melanoma deposits after intravenous administration of Reolysin®.

III. Assess the impact of pre-existing anti-reoviral immunity (as represented by p38 expression in pretreatment tumor specimens) on the efficacy and toxicity of Reolysin®.

IV. To measure the effect of Reolysin® on the immune system, in terms of dendritic cell activation, T-cell activation, presence of Treg cells in tumor specimens, and the frequency of T cells, B cells, NK cells, and peptide specific cytotoxic T lymphocytes reactive against melanoma differentiation antigen peptides (gp100, MART-1, and tyrosinase).

V. To assess the induction of melanoma specific immune response, in terms of the presence of melanoma differentiation antigens (gp100, MART-1, and tyrosinase) in tumor specimens.

OUTLINE: This is a multicenter study.

Patients receive wild-type reovirus (Reolysin®) IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Some patients undergo tumor tissue samples collection at baseline and at 1 week after initiation of treatment for correlative laboratory studies. Tissue samples are analyzed for p38/MAPK activation status by IHC; reoviral replication in metastatic deposits by electron microscopy; and immunologic parameters by IHC. Blood samples are collected at baseline and periodically during the study. Blood samples are analyzed for immunologic parameters by tetramer and ELISPOT technology and for neutralizing antibodies against reovirus.

After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 5 years.

Conditions

Recurrent Melanoma; Stage IV Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (viral therapy)

Patients receive wild-type reovirus (Reolysin®) IV administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

wild-type reovirus

Intervention Type: BIOLOGICAL

Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.

Interventions

wild-type reovirus

Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.

Intervention Type: BIOLOGICAL

Other Intervention Names

REOLYSIN

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed malignant melanoma

• All melanomas, regardless of origin, are allowed
• Metastatic disease
• Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20mm by conventional techniques or as ≥ 10 mm by spiral CT scan
• Must have ≥ 1 metastatic lesion that can be safely biopsied
• Must have received ≥ 1 prior treatment for metastatic disease
• Not a candidate for curative surgery for metastatic disease
• No known brain metastases
• Eastern Cooperative Oncology Group performance status 0-2
• Life expectancy > 12 weeks
• Total White Blood Cell (WBC) ≥ 3,000/mcL
• Absolute neutrophil count ≥ 1,500/mcL
• Platelet count ≥ 100,000/mcL
• Hemoglobin ≥ 9 g/dL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• Aspartate Aminotransferase (AST) ≤ 2.5 times ULN
• Creatinine ≤ 1.5 times ULN
• Troponin-T normal
• Left ventricular ejection fraction (LVEF) ≥ 50% by ECHO or MUGA
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Agrees to provide blood and tissue samples for the mandatory translational research component of the study
• Must be able to avoid direct contact with pregnant or nursing women, infants, and immuno compromised individuals during study and for ≥ 3 weeks following the last dose of study agent
• No concurrent uncontrolled illness including, but not limited to, any of the following:

• Ongoing or active infection
• Symptomatic congestive heart failure
• Unstable angina pectoris, cardiac arrhythmia, or myocardial infarction within the past year
• Psychiatric illness/social situation that would preclude study compliance
• No known HIV positivity

• Patients with a clinical history suggestive of an immuno compromised status are required to undergo HIV testing
• More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas) and recovered
• More than 2 weeks since prior radiotherapy, immunotherapy, or treatment with small molecule cell cycle inhibitors
• No other concurrent investigational agents
• No other concurrent anticancer therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Evanthia Galanis

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

NCI-2009-00233

Identifier Type: REGISTRY

Identifier Source: secondary_id

MAYO-MC0672

Identifier Type: -

Identifier Source: secondary_id

7848

Identifier Type: -

Identifier Source: secondary_id

CDR0000592801

Identifier Type: -

Identifier Source: secondary_id

MC0672

Identifier Type: OTHER

Identifier Source: secondary_id

7848

Identifier Type: OTHER

Identifier Source: secondary_id

N01CM00070

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2009-00233

Identifier Type: -

Identifier Source: org_study_id